Literature DB >> 28737973

Current Treatment Landscape of Advanced Papillary Renal Cancer.

Brian Shuch1, Andrew W Hahn1, Neeraj Agarwal1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28737973     DOI： 10.1200/JCO.2017.74.3328

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma.

Authors:  Mushi Ye; Zhuobin He; Wei Dai; Zhuo Li; Xiaojun Chen; Jianjun Liu
Journal:  Oncol Lett       Date:  2018-07-19       Impact factor: 2.967

Review 2.  Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities.

Authors:  Deepika Sirohi; Steven C Smith; Neeraj Agarwal; Benjamin L Maughan
Journal:  Res Rep Urol       Date:  2018-11-15

3.  Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation.

Authors:  Ayham Al Ahmad; Vanessa Paffrath; Rosanna Clima; Jonas Felix Busch; Anja Rabien; Ergin Kilic; Sonia Villegas; Bernd Timmermann; Marcella Attimonelli; Klaus Jung; David Meierhofer
Journal:  Cancers (Basel)       Date:  2019-09-03       Impact factor: 6.639

4.  Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma.

Authors:  Qi Wang; Yang Zhang; Bolei Zhang; Yao Fu; Xiaozhi Zhao; Jing Zhang; Ke Zuo; Yuexian Xing; Song Jiang; Zhaohui Qin; Erguang Li; Hongqian Guo; Zhihong Liu; Jingping Yang
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 14.919

5.  Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.

Authors:  Roma Pahwa; Janhavi Dubhashi; Anand Singh; Parthav Jailwala; Alexei Lobanov; Craig J Thomas; Michele Ceribelli; Kelli Wilson; Christopher J Ricketts; Cathy D Vocke; Catherine Wells; Donald P Bottaro; W Marston Linehan; Len Neckers; Ramaprasad Srinivasan
Journal:  J Exp Clin Cancer Res       Date:  2022-06-27

Review 6.  Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.

Authors:  Ieman A M Aljahdali; Renyuan Zhang; Fengzhi Li; Kent L Nastiuk; John J Krolewski; Xiang Ling
Journal:  J Exp Clin Cancer Res       Date:  2021-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.